Intraperitoneal Cisplatin Plus Intravenous Cyclophosphamide Versus Intravenous Cisplatin Plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
December 26, 1996
Does IP cisplatin improve survival over IV cisplatin when combined with IV cyclophosphamide after surgical resection of advanced epithelial ovarian cancer?
IV cyclophosphamide 600mg/m2 day 1IV cisplatin 100mg/m2 day 1q3wks x6 cycles
IV cyclophosphamide 600mg/m2 day 1IP cisplatin 100mg/m2q3wks x6 cycles
PDS to ≤2cm residualepithelial ovarian cancerstage III
IV (n=279) vs IP (n=267):58% in both groups completed 6 cycles of cisplatincomplete response: 36% vs 47%median OS: 41 vs 49 mos (SS)more leukopenia/neuro toxicity in IV arm
IP cisplatin improves survival in women with stage III epithelial ovarian cancer after resection to ≤2cm residual disease